P2Y1-receptors in human platelets which are pharmacologically distinct from P2YADP-receptors

被引:95
作者
Fagura, MS [1 ]
Dainty, IA [1 ]
McKay, GD [1 ]
Kirk, IP [1 ]
Humphries, RG [1 ]
Robertson, MJ [1 ]
Dougall, IG [1 ]
Leff, P [1 ]
机构
[1] Astra Charnwood, Dept Pharmacol, Loughborough LE11 5RH, Leics, England
关键词
P2Y(1)-receptors; Jurkat cells; human washed platelets; receptor reserve; intracellular calcium measurements; ATP; ADP; AR-C66096; adenosine-3 '-phosphate-5 '-phosphate;
D O I
10.1038/sj.bjp.0701827
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 In the present study we have classified the receptor(s) mediating increases in intracellular calcium concentration ([Ca2+](i)) in human washed platelets and compared the pharmacological profile obtained with that observed in Jurkat cells, stably transfected with a bovine P2Y(1)-receptor. 2 The P2Y(1)-receptor antagonist, adenosine-3'-phosphate-5'-phosphate (A3P5P), competitively antagonized agonist responses in both Jurkat cells, and in platelets with similar affinities (pK(B) of 5.8 and 6.0, respectively). 3 The selective P2Y(ADP) antagonist, AR-C66096, exhibited partial agonism in the Jurkat cells with an affinity (pK(A)) of 4.9. This value is consistent with its known P2Y(1)-receptor activity. In platelets, AR-C66096 at a concentration (0.1 mu M) approximately 100 fold greater than its known P2Y(ADP) receptor affinity, had no effect on ADP-induced increases in [Ca2+](i). 4 4 The ability of adenine nucleotide analogues to elevate [Ca2+](i) in the Jurkat cells was also determined. The rank order of agonist potency (p[A](50)) was: 2-MeSADP (8.3) > 2-ClATP (7.8) > ADP (7.5) = 2-MeSATP (7.4) > ATP gamma S (6.5) > ATP (6.2), with ATP appearing to be a partial agonist. 5 The same rank order of potency was observed when similar experiments were performed in platelets. However, the absolute potencies of all the agonists and the intrinsic activities of both ATP gamma S and ATP were lower in platelets. 6 The operational model of agonism was used to test whether the agonist concentration-effect profiles obtained in these two cell types could be explained on the basis of differences in receptor reserve. The analysis indicated that the data obtained in platelets closely resembled that predicted for a low density or poorly coupled P2Y(1)-receptor system. 7 The hypothesis that the observed partial agonist behaviour of ATP was the result of receptor activation by contaminating ADP with concomitant receptor blockade by ATP, was tested in the platelet system. This hypothesis was supported by a theoretical analysis, which yielded an affinity value for ATP similar to that obtained previously at P2Y(1)-receptors. 8 In summary, the results of this study indicate that human washed platelets contain P2Y(1)-receptors which mediate increases in [Ca2+](i) and that this receptor population is pharmacologically distinct from P2Y(ADP)-receptors.
引用
收藏
页码:157 / 164
页数:8
相关论文
共 39 条
[1]   OPERATIONAL MODELS OF PHARMACOLOGICAL AGONISM [J].
BLACK, JW ;
LEFF, P .
PROCEEDINGS OF THE ROYAL SOCIETY SERIES B-BIOLOGICAL SCIENCES, 1983, 220 (1219) :141-162
[2]   AN OPERATIONAL MODEL OF PHARMACOLOGICAL AGONISM - THE EFFECT OF E/[A] CURVE SHAPE ON AGONIST DISSOCIATION-CONSTANT ESTIMATION [J].
BLACK, JW ;
LEFF, P ;
SHANKLEY, NP ;
WOOD, J .
BRITISH JOURNAL OF PHARMACOLOGY, 1985, 84 (02) :561-571
[3]   POTENT AGONIST ACTION OF 2-THIOETHER DERIVATIVES OF ADENINE-NUCLEOTIDES AT ADENYLYL CYCLASE-LINKED P-2Y-PURINOCEPTORS [J].
BOYER, JL ;
OTUEL, JW ;
FISCHER, B ;
JACOBSON, KA ;
HARDEN, TK .
BRITISH JOURNAL OF PHARMACOLOGY, 1995, 116 (06) :2611-2616
[4]  
Boyer JL, 1996, MOL PHARMACOL, V50, P1323
[5]  
Burnstock G, 1996, DRUG DEVELOP RES, V38, P67, DOI 10.1002/(SICI)1098-2299(199605)38:1<67::AID-DDR9>3.0.CO
[6]  
2-J
[7]  
CATTANEO M, 1992, BLOOD, V80, P2787
[8]  
CONLEY P, 1996, DRUG DEVELOP RES, V37, P111
[9]  
Cusack NJ, 1996, DRUG DEVELOP RES, V37, P212, DOI 10.1002/(SICI)1098-2299(199604)37:4<212::AID-DDR3>3.0.CO
[10]  
2-O